Rosenberg Noah L. 4
4 · Verrica Pharmaceuticals Inc. · Filed Nov 25, 2025
Insider Transaction Report
Form 4
Transactions
- Purchase
Series C Warrant (right to buy)
2025-11-25+589→ 589 totalExercise: $6.32Exp: 2030-11-25→ Common Stock (589 underlying) - Purchase
Common Stock
2025-11-25$4.24/sh+2,357$10,000→ 2,357 total
Footnotes (2)
- [F1]Immediately exercisable.
- [F2]The reported securities are included within 2,357 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.